CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BMS-986322 PlaceboWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug3268 famotidine Wiki 1.00
drug356 BMS-986322 Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D000437 Alcoholism NIH 0.58
D019966 Substance-Related Disorders NIH 0.33

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986322 in Healthy Participants Including an Open-label Assessment of Food and pH Effects on Relative Bioavailability of BMS-986322

A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.

NCT04175925 Healthy Participants Drug: BMS-986322 Other: BMS-986322 Placebo Drug: famotidine

Primary Outcomes

Measure: Incidence of Death

Time: up to 12 months

Measure: Incidence of Adverse Effects (AEs)

Time: up to 12 months

Measure: Incidence of Adverse Events leading to discontinuation

Time: up to 12 months

Measure: Incidence of Serious Adverse Events (SAEs)

Time: up to 12 months

Measure: Vital signs of body temperature

Time: up to 12 months

Measure: Vital signs of blood pressure

Time: up to 12 months

Measure: Vital signs of respiratory rate

Time: up to 12 months

Measure: Number of Participants with abnormal physical examinations

Time: up to 12 months

Measure: Number of clinically significant changes in Electrocardiograms (ECGs)

Time: up to 12 months

Measure: Number of clinically significant changes in lab assessment of blood serum

Time: up to 12 months

Measure: Number of clinically significant changes in lab assessment of urine

Time: up to 12 months

Measure: Number of Clinically significant changes in lab assessment of blood

Time: up to 12 months

Measure: Maximum concentration (Cmax) of BMS-986322 in Part C

Time: up to 12 months

Measure: Time of maximum concentration (Tmax) of BMS-986322 in Part C

Time: up to 12 months

Measure: Terminal elimination rate constant (Lambda_z) of BMS-986322 in Part C

Time: up to 12 months

Measure: Terminal elimination half-life (T-Half) of BMS-986322 in Part C

Time: up to 12 months

Measure: Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)] of BMS-986322 in Part C

Time: up to 12 months

Measure: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)] of BMS-986322 in Part C

Time: up to 12 months

Measure: Apparent oral clearance (CL/F) of BMS-986322 in Part C

Time: up to 12 months

Measure: Apparent volume of distrubution at terminal phase (Vz/F) of BMS-986322 in Part C

Time: up to 12 months

No related HPO nodes (Using clinical trials)